These results suggest that in addition to the increased ER and VDR expression, the intact VDR signaling machinery as present in ER-positive, vitamin D-sensitive cells is essential for the antiproliferative action of vitamin D, whereas the direct VDR target genes such as CYP24 can remain responsive to augmented VDR expression.
Introduction
The role of estrogen receptor (ER) a in breast cancer has been extensively studied and is a well-established major target for breast cancer treatment (1) (2) (3) . ER-positive breast cancer cells are generally more responsive to antiestrogen therapy and chemopreventive agents, including retinoids, vitamin D analogs, tamoxifen, in comparison with ERnegative breast cancer cells (4, 5) . The action of vitamin D is mediated via vitamin D receptor (VDR) and yet the mechanism underlying the responsiveness of ER-positive cells to vitamin D analogs remains to be elucidated. There are reports that in ER-positive breast cancer cells vitamin D effect may resemble antiestrogenic effects. However, the literature has provided several contradictory results. For example, some investigations support the concept that the antitumor effects of vitamin D analogs on ER-positive human breast cancer cells are mediated via disruption of estrogen-mediated mitogenic and survival signals (6) (7) (8) . However, resistance of ER-positive MCF-7 sublines to vitamin D has also been widely reported. Jensen et al. (9) showed that the sensitivity to growth suppression by 1,25-dihydroxyvitmain D 3 among MCF-7 clones correlates with VDR protein induction, whereas Narvaez et al. (10) demonstrated that a vitamin D3-resistant MCF-7 variant (MCF-7 D3Res ) expressed comparable level of functional VDR protein in comparison with the sensitive parental MCF-7 cells, the VDR was uncoupled from a functional apoptotic pathway. Hansen et al. (11) developed another vitamin D-resistant MCF-7 cell line with increased sensitivity to the pure antiestrogen ICI182780. Overall, in ER-positive, vitamin D-resistant MCF-7 cells, there seems to be significant dissociation between ER and VDR signaling, since the ER-positive cells remained sensitive to antiestrogens (10, 11) . In ER-negative MDA-MB231 breast cancer cells that are relatively resistant to the antiproliferative effect of vitamin D, the gene expression pattern induced by 1,25(OH) 2 D 3 was also very different from that in MCF-7 cells (12) . This provides an ideal model where one can understand the interactions between ER-and VDR-mediated functions by stably transfecting ER and/or VDR in ER-negative breast cancer cells. In this report, we designed experiments to test whether ER-negative cells become responsive to 1a-hydroxyvitamin D 5 (13) . 1a(OH)D 5 is less toxic in comparison with other vitamin D analogs and at 1 lM, 1a(OH)D 5 showed significant inhibition of the development of carcinogen-induced mammary alveolar and ductal lesions in mouse mammary gland organ culture without any signs of cytotoxicity (13) . The main mode of action reported for vitamin D analogs is via binding to the VDR resulting in the regulation of key genes involved in antiproliferation, differentiation and/or apoptosis (14) . 1a(OH)D 5 has been shown to be most effective in cell lines that express high levels of VDR, such as the ER-positive BT-474 breast carcinoma cells, whereas cell lines with low levels of VDR, such as the MDA-MB-231 have been shown to be less responsive to 1a(OH)D 5 (5) . The purpose of the present study was to evaluate whether ER or VDR overexpression in ER-negative, vitamin D-resistant MDA-MB231 cells increases the sensitivity to 1a(OH)D 5 treatment.
propidium iodide staining solution with RNAase A for 30 min and then analyzed by a Coulter EPICS Elite ESP Flow Cytometer (Coulter Corp., Miami, FL). At least 10 000 cells from both control and 1a(OH)D 5 -treated cells were analyzed for cell cycle distribution (17) . BrdU incorporation assay was performed using a kit from Calbiochem (La Jolla, CA) according to the manufacturerÕs instructions. Cells were seeded in 96-well plates at 2000 cells per well, treated with vitamin D for 48 h and BrdU was added to the medium 6 h before termination of the experiment. BrdU incorporation assay is a more sensitive assay for cell proliferation that was used to evaluate cell proliferation potential in S30 cells transiently transfected with VDR.
Western blot
When cells grew to 50-70% confluence, cell lysates were prepared and subjected to western blot analysis as described previously (4) . Rat anti-VDR monoclonal antibody and ER mouse monoclonal antibody were purchased from NeoMarkers (Freemont, CA). CYP24 mouse polyclonal antibody was from Abnova Corp. (Taipei, Taiwan). All secondary antibodies were from Santa Cruz Biotech (Santa Cruz, CA).
Transfection of VDR in MDA-MB231 and S30 cells
The VDR expression vector pcDNA3.1VDR was generated by PCR cloning using pcDNA3.1/V5-His TOPO TA Expression Kit (Invitrogen, Carlsbad, CA). The open reading frame of VDR was isolated by PCR of full-length cDNA from T47D cells using primers containing start and stop codons and BamH1 site (VDR-start, 5#-CACCGGATCCGGGATGGAGGCAATGGCGG-CC-3#, VDR-stop, 5#-GAATGGATCCTAGTCAGGAGATCTCATTGCC-3#). pcDNA3.1 empty vector and pcDNA3.1VDR expression vector were used for stable transfection of MDA-MB231 cells to generate control (MB231 vector ) and VDR-expressing (MB231 VDR ) cell lines. Nearly confluent cells grown in 10 cm dish were transfected with empty pcDNA3.1 or pcDNA3.1VDR using Lipofectomine 2000 (Invitrogen) (17) . Cells were transfected with 10 lg per dish expression vector. After 5 h incubation, transfected cells were incubated in fresh medium containing 10% FBS for 24 h, then cells were subjected to selection with G418 (1 mg/ml). After 3 week selection, all clones resistant to G418 selection were pooled together to generate two cell lines: MB231 vector and MB231 VDR . These cell lines were used to test cellular response to 1a(OH)D 5 . . Transient transfection of S30 cells was performed similarly, however, without G418 selection, 24 h following transfection, transfected cells were divided to dishes and plates, treated with vitamin D and subjected to different assays.
RNA extraction and real-time reverse transcription-polymerase chain reaction (RT-PCR) Total RNA extraction and RT reaction were performed as described previously (4) . RNA was further subjected to DNase I (Ambion, Austin, TX) digestion and purification using RNease Mini Kit (Qiagen, Valencia, CA) before RT. Two RT reactions for each sample were pooled and diluted with equal amount of DNase/Rnase-free water. Real-time PCR was performed with 2 ll diluted RT product in a MyiQ Real-time PCR Detection System (Bio-Rad, Hercules, CA) by using iQ TM SYBR Green PCR Supermix (Bio-Rad) according to manufacturer's guidelines. The PCR cycling conditions used were 40 cycles of 15 s at 95°C, 15 s at 60°C and 20 s at 72°C. Fold inductions were calculated using the formula 2 À(DDCt) , where DDCt is DCt (treatment) À DCt (control) , DCt is Ct (target gene) À Ct (actin) and Ct is the cycle at which the threshold is crossed. The gene-specific primer pairs (and product size) for the gene analyzed here were as follows: VDR gene forward 5#-TGAAGCGG-AAGGCACTATTCACCT-3# and reverse 5#-ACTCCTTCATCATGCC-GATGTCCA-3# (123 bp), Prohibitin gene forward 5#-ACCACGTAATGTGCCAGTCA-3# and reverse 5#-TAGTCC-TCTC-CGATGCTGGT-3# (126 bp), CYP24 gene forward 5#-CTCAGCAGCC-TAGTGCAGATT-3# and reverse 5#-ACTGTTTGCTGTCGTTTCCAC-3# (122 bp), b-actin forward 5#-CTCTTCCAGCCT-TCCTTCCT-3# and reverse 5#-AG-CACTGTGTTGGCG-TACAG-3# (116 bp), ERa gene forward 5#-GGAGGGC-AGGGGTGAA-3# and reverse 5#-GGCCAGGCTGTTCTTCTTAG-3# (101 bp), progesterone receptor (PgR) gene forward 5#-GATTCAGAAGCCAGCCAGAG-3# and reverse 5#-CAGCTCCCACAGGT-AAGGAC-3# (119 bp), NCoR1 gene forward 5#-GAGCATTTGAAGGTGCCATT-3# and reverse 5#-GCTCTGGAC-CACTTCTGGAG-3# (143 bp), SRC1 forward 5#-AAATGATCCCGCACTGA-GAC-3# and reverse 5#-CCGCCTACCAGATTCACTGt-3# (147 bp). PCR product quality was monitored using post-PCR melt curve analysis.
Results
ER expression in MDA-MB231 cells does not increase cellular sensitivity to 1a(OH)D 5 We first examined cellular sensitivity to 1a(OH)D 5 using MTT assay in both the parental ER-negative MDA-MB231 and ER-transfected MDA-MB231 (S30) cells and compared them with ER-positive BT474 breast cancer cells. As shown in Figure 1A (18) and increased VDR transcriptional level at early time points. In comparison with BT474 cells, both MDA-MB231 and S30 cells expressed low basal level of VDR at mRNA and protein levels.
ERa and PgR expression
To verify the ERa expression in S30 cells and to determine if ERa is regulated by 1a(OH)D 5 in BT474 cells, ERa expression was assessed at transcriptional level using real-time RT-PCR and at protein level using western blotting ( Figure 3A and B). Considering the potential role of PgR in ERa signaling in breast cancer cells, PgR mRNA was also analyzed at the same time ( Figure 3C ). As shown in Figure 3 Figure 5A ). At protein level, MB231 VDR cells expressed significant higher level of VDR than the control cell line MB231 vector , but the VDR protein level was still lower than that of BT474 cells ( Figure 5B ) regardless of the comparable transcriptional VDR level in MB231 VDR and BT474 cells. 
Overexpression of ER and VDR in MDA-MB231 and vitamin D response
Further characterization demonstrated that VDR direct target gene CYP24 was more responsive to 1a(OH)D 5 treatment in MB231 VDR cells than that in parental MDA-MB231 cells and control MB231 vector cells ( Figure 5C ), which is correlated to its increased VDR expression level. Cell sensitivity for the antiproliferative effect of 1a(OH)D 5 was determined by using MTT assay and the results demonstrated that MB231 VDR cells were still resistant to 1a(OH)D 5 ( Figure 5D ), which is similar to that of parental MDA-MB231 cells, suggesting that the functional VDR was uncoupled with its functional antiproliferative pathway in this cell line.
Transient transfection of VDR in S30 cells failed to restore sensitivity to 1a(OH)D 5
Since VDR transfection did not restore the sensitivity to 1a(OH)D 5 in MDA-MB231 cells, it was considered possible that both VDR and ER may be required to respond to vitamin D. We therefore transiently transfected S30 cells with VDR expression vector to restore the VDR level to test if VDR overexpression sensitizes the cells for the antiproliferative effect of 1a(OH)D 5 . As shown in Figure 6A , transient transfection of VDR (S30 VDR ) caused extremely high level of VDR transcription as examined by quantitative RT-PCR, but the VDR protein expression is still not as high as in BT474 cells, although it is much higher than that of control vector-transfected S30 cells ( Figure 6B ). Similar to that of MB231 VDR cells, further characterization demonstrated that VDR direct target gene CYP24 was more responsive to 1a(OH)D 5 treatment in S30 VDR cells than that in control S30 vector cells ( Figure 6C ) that is correlated to its increased VDR expression level. BrdU incorporation assay did not show increased sensitivity of VDR-transfected S30 cells to both 1a(OH)D 5 and 1,25(OH) 2 D 3 for their antiproliferative effects after 48 h treatment ( Figure 6D ). This result was confirmed using MTT and crystal violet assays after 4 and 6 day treatment with 1a(OH)D 5 and 1,25(OH) 2 D 3 (data not shown).
Discussion
Breast cancer is generally characterized by estrogen-dependent growth, and the proliferative actions of estrogen are mediated via ER. Hence, presence or absence of ER is critical to the cell and forms the basis for its classification. The mechanism of action of ER is similar to other nuclear receptors. The binding of ligand induces an activating conformational change in the ER, leading to homodimerization and binding to specific DNA response elements (ERE) within the regulatory regions of the target gene (19) . ER-positive cells are usually well differentiated and represent a phenotype that is more amenable to treatment. Some studies have suggested a cross talk between 1,25(OH) 2 D 3 and estrogen-signaling pathway (6, 7) . In ERpositive breast cancer cells such as MCF-7 cells, the antitumor effects of 1,25(OH) 2 D 3 may be secondary to disruption of estrogen-mediated survival signals (20) . One way to understand the role of ER and vitamin D function is to introduce ER into ER-negative breast cancer cells and evaluate the role of vitamin D on cell proliferation. Thus, the current study is an attempt to address the role of ER in VDR signaling by using ER-negative cells overexpressing exogenous functional ER and VDR and determining the antiproliferative effects of 1a(OH)D 5 . In our previous studies, we have consistently observed similar effects of both 1a(OH)D 5 and 1,25(OH) 2 D 3 except that 1a(OH)D 5 needs higher dose to reach similar effects of 1,25(OH) 2 D 3 (5, 13, 21) ; this study mainly focused on cellular response to 1a(OH)D 5 .
We first compared the differential sensitivity of three breast cancer cell lines in response to 1a(OH) Figure 2B ), although MDA-MB231 and S30 cells were still resistant. This suggests that VDR protein level might not be the key factor for vitamin D resistance in these cell lines. This has been previously reported in vitamin D3-resistant MCF-7 variant, where VDR protein level was comparable with sensitive parental MCF-7 cells, but VDR was uncoupled from a functional apoptotic pathway (10) .
The VDR introduction to MDA-MB231 (MB231 VDR ) cells is similar to ER introduction to MDA-MB231 cells (S30). In both cell types (S30 and MB231 VDR ), the respective target genes TGFa (for ER) and CYP24 (for VDR) were more responsive to estradiol (23) and 1a(OH)D 5 , respectively, ( Figure 5C ). However, the signaling pathways related to their cell proliferation in response to these ligands were not restored. Similar results have also been reported for ERb introduction to MDA-MB231 cells; the ERb transfection did not cause significant cell growth regulation when treated with estrogen (23) . These results may suggest that there is a profound signaling alteration of nuclear receptor-mediated proliferation in ER-negative MDA-MB231 cells in comparison with ER-positive breast cancer cells such as MCF-7 and BT474 cells. Restoration of certain nuclear receptor in MDA-MB231 cells may only partially restore the responsiveness of its primary target genes and be unable to fully restore the cell proliferation regulatory function of the steroid receptor in response to the respective Overexpression of ER and VDR in MDA-MB231 and vitamin D response ligand. Regulation of cell proliferation is much more complex as compared with single target gene regulation; treatment of ER-negative breast cancer might need strategy other than restoring single nuclear receptor expression. It has been recently reported that cotreatment of MDA-MB231 cells with histone deacetylation inhibitor trichostatin A dramatically increased the sensitivity to the antiproliferative effect of 1,25(OH) 2 D 3 (24) . Consistently, our recent data also showed that cotreatment of MDA-MB231 cells with trichostatin A significantly enhanced the antiproliferative effect induced by 1a(OH)D 5 (data not shown). These data suggest that silencing of multiple genes related to proliferation regulation through histone deacetylation-mediated chromatin condensation could compose at least part of the mechanism underlying the resistance to vitamin D in MDA-MB231 cells.
In exploring the insensitivity of MDA-MB231 and S30 cells, we further compared nuclear cofactors (CoRs and CoAs) that potentially affect VDR function in these three cell lines. CoR proteins, such as NCoR, SMRT and Alien, link non-liganded, DNA-bound VDR-RXR heterodimers to enzymes with histone deacetylase activity that cause chromatin condensation (25) . This gives VDR intrinsic repression properties comparable with retinoic acid and thyroid hormone receptors. CoA proteins such as SRC1, TIF and RAC3 (26) , link the ligandactivated VDR to enzymes displaying histone acetyltransferase activity that cause chromatin opening. The conformational change within VDR's ligand-binding domain after binding of 1,25(OH) 2 D 3 or its analog results in replacing a CoR by a CoA protein. Ligand-activated VDR-RXR heterodimers fulfill two tasks, opening chromatin and activating transcription (27) . We initially hypothesized that BT474 cells would express low level of CoR and high level of CoA at transcriptional level. Elevated NCoR1 has been reported to attenuate VDR signaling in breast cancer cells (28) , whereas SRC1 increases VDR-DNA binding and enhances function (29, 30) . To our surprise, MDA-MB231 and S30 cells expressed lower transcriptional levels of both NCoR1 and SRC1 in comparison with that of BT474 cells, whereas S30 cells expressed lowest SRC1 among the three cell lines. Whether the low level of NCoR1 in the two cell lines is correlated to its higher basal level of CYP24 still requires further investigation; it is possible that high level of CoR and CoA in BT474 can help to tightly and precisely control the CYP24 transcription. The magnitude of CYP24 transcription induced by 1a(OH)D 5 in BT474 cells is much greater than that in MDA-MB231, S30, MB231 VDR and S30 VDR cells. The high level of NCoR1 in BT474 and the cellular responsiveness to 1a(OH)D 5 are in contrast to a proposed model whereby elevated CoR levels lead to epigenetic silencing of the transcriptional responsiveness of key antiproliferative target genes and insensitivity to vitamin D (24, 28) . This suggests another possible biological significance of CoRs-tight control of transactivaiton mediated by nuclear receptor ligands; further investigation is needed to address this issue.
In summary, loss of ER in breast cancer cells appear to be irreversible, there is profound alteration in proliferation signaling mediated by ER and VDR, since introduction of exogenous ER and VDR in ERnegative breast cancer cells failed to restore the sensitivity to the antiproliferative effect of 1a(OH)D 5 . Endogenous VDR, although expressed at lower basal level, is functional in both MDA-MB231 cells and S30 cells, since VDR direct target gene CYP24 was responsive to 1a(OH)D 5 treatment. Low levels of NCoR1 and SRC1 were observed in MDA-MB231 and S30 cells in comparison with BT474 cells; these proteins could also contribute to the cellular sensitivity to vitamin D treatment in these cells. These studies further our understanding on vitamin D resistance in ER-negative breast cancer cells and the biological significance of nuclear receptor CoRs in ER-positive breast cancer cells in response to 1a(OH)D 5 .
